Serum Levels of Omentin in Pseudoexfoliation Syndrome
Yasin Yücel Bucak, Mehmet Tosun, Hüseyin Simavlı, Halil İbrahim Önder, Mesut Erdurmuş
Abstract
Yasin Yücel Bucak, Mehmet Tosun, Hüseyin Simavlı, Halil İbrahim Önder, Mesut Erdurmuş
Abstract
PURPOSE: Omentin, a member of the adipocytokines family, is derived from adipose tissue and a lower level of serum omentin is considered as a metabolic risk factor. The aim of the present study is to evaluate the serum levels of omentin in patients with pseudoexfoliation syndrome (PES). MATERIALS AND METHODS: Patients without any systemic or ocular disease other than PES were included in the study. Age-matched and sex-matched healthy volunteers without PES were accepted as a control group. After detailed ophthalmologic examination, blood samples were obtained from a forearm vein. Serum levels of omentin were determined by the method of enzyme-linked immunosorbent assay. RESULTS: The mean age of the PES group (12 females, 12 males, n=24) was 75.2 ± 8.4 years, and the control group (10 females, 10 males, n=20) was 75 ± 6.7 years. There was no difference between the groups in terms of age (P=0.93) and sex (P=0.9). The mean serum levels of omentin in the PES group were 801.5 ± 317.1 ng/mL and in the control group were 1150.1 ± 584.1 ng/mL. The mean serum omentin levels were significantly lower in patients with PES (P=0.016). CONCLUSION: Lower levels of serum omentin in patients with PES compared with healthy subjects may support the theory of systemic nature of the disease.
OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
PURPOSE: Omentin, a member of the adipocytokines family, is derived from adipose tissue and a lower level of serum omentin is considered as a metabolic risk factor. The aim of the present study is to evaluate the serum levels of omentin in patients with pseudoexfoliation syndrome (PES). MATERIALS AND METHODS: Patients without any systemic or ocular disease other than PES were included in the study. Age-matched and sex-matched healthy volunteers without PES were accepted as a control group. After detailed ophthalmologic examination, blood samples were obtained from a forearm vein. Serum levels of omentin were determined by the method of enzyme-linked immunosorbent assay. RESULTS: The mean age of the PES group (12 females, 12 males, n=24) was 75.2 ± 8.4 years, and the control group (10 females, 10 males, n=20) was 75 ± 6.7 years. There was no difference between the groups in terms of age (P=0.93) and sex (P=0.9). The mean serum levels of omentin in the PES group were 801.5 ± 317.1 ng/mL and in the control group were 1150.1 ± 584.1 ng/mL. The mean serum omentin levels were significantly lower in patients with PES (P=0.016). CONCLUSION: Lower levels of serum omentin in patients with PES compared with healthy subjects may support the theory of systemic nature of the disease.
Key concepts: Medicine, Pseudoexfoliation syndrome, Pseudoexfoliation, Glaucoma, Ophthalmology, Internal medicine